Understanding Endometriosis
Endometriosis is a chronic condition where endometrial tissue grows outside the uterus, causing pain, inflammation, and potential fertility challenges. This comprehensive guide covers diagnosis, treatment options, and management strategies for this complex condition affecting millions worldwide.
prof Mykhailo Medvediev
What Is Endometriosis?
The Condition
Endometriosis occurs when endometrial glands and stroma exist outside the uterine cavity. These implants are typically found in the pelvis but can occur throughout the body, including the bowel, diaphragm, and pleural cavity.
This ectopic endometrial tissue causes inflammation, scarring, and can lead to debilitating symptoms. The condition is estrogen-dependent and affects individuals during premenarcheal, reproductive, and postmenopausal stages.
Peak Prevalence and Age Distribution
25-35
Peak Age Range
Years of age when endometriosis prevalence is highest
7-8
Diagnostic Delay
Average years from symptom onset to diagnosis
58%
Multiple Visits
Patients requiring multiple GP visits before evaluation
While most common during reproductive years, endometriosis has been reported in premenarcheal girls and postmenopausal individuals. Early recognition and diagnosis are crucial for effective management.
Common Presenting Symptoms
Pelvic Pain
Chronic abdominal/pelvic pain described as dull, throbbing, sharp, or burning. Often the primary presenting complaint.
Dysmenorrhea
Severe menstrual pain that significantly impacts quality of life and daily activities.
Dyspareunia
Pain during sexual intercourse, which can be deep (proximal) or superficial (distal).
Infertility
Difficulty conceiving, affecting reproductive health and family planning goals.
Additional Symptoms
Bowel and Bladder
  • Painful urination (dysuria)
  • Urinary frequency and urgency
  • Painful bowel movements (dyschezia)
  • Diarrhea or constipation
  • Bowel cramping
Systemic Effects
  • Heavy menstrual bleeding
  • Low back pain
  • Chronic fatigue
  • Nausea or vomiting
  • Irregular bleeding
Symptom Constellation and Diagnosis
Research shows that individuals with endometriosis are significantly more likely to report multiple symptoms simultaneously. In one cohort study, 20% of women with endometriosis reported five to seven symptoms compared with only 2% of unaffected women.
20%
Multiple Symptoms
Women with endometriosis reporting 5-7 symptoms
2%
Control Group
Unaffected women with similar symptom burden
While increasing symptom numbers correlate with higher likelihood of endometriosis, symptom constellations alone cannot definitively diagnose the condition. Some individuals remain asymptomatic and are diagnosed incidentally during surgery for other indications.
Types of Dyspareunia
Deep (Proximal) Dyspareunia
Deeply infiltrating endometriosis lesions on uterosacral ligaments, cardinal ligaments, pouch of Douglas, posterior vaginal fornix, and anterior rectal wall contribute to deep sexual pain.
Superficial (Distal) Dyspareunia
Introital or superficial pain resulting from lesions of the cervix, hymen, perineum, and episiotomy scars.
Urinary and Bowel Manifestations
Bladder Endometriosis
Presents with nonspecific urinary symptoms including frequency, urgency, and pain during urination. Symptoms often worsen during menstruation.
Ureteral endometriosis may be asymptomatic or associated with colicky flank pain or gross hematuria.
Bowel Involvement
Women with bowel endometriosis experience diarrhea, constipation, dyschezia, and bowel cramping.
Deep infiltrating endometriosis of the posterior cul-de-sac and rectovaginal septum typically causes dyspareunia and painful defecation. Rectal bleeding is rare.
Extrapelvic Manifestations
Abdominal Wall
Painful abdominal wall mass with cyclic or continuous pain, often with bleeding.
Thoracic
Chest pain, pneumothorax, hemothorax, hemoptysis, or scapular/cervical pain, often catamenial.
Vulvar
Cyclic bleeding and pain in vulvar tissue, though less common.
Natural History and Disease Progression
The natural course of endometriosis varies significantly among individuals. The number of peritoneal areas affected appears to increase during adolescence until the early 20s, but not all disease progresses.
Studies using second-look laparoscopy 6-12 months after initial diagnosis found that disease progressed in 29-45% of untreated women, regressed in 22-29%, and remained stable in 33-42%. Factors determining progression, regression, or stability remain unknown.
The Challenge of Diagnostic Delay
A Persistent Problem
Diagnostic delays of seven to eight years are commonly reported by patients ultimately diagnosed with endometriosis. This significant delay impacts quality of life, treatment outcomes, and disease progression.
58%
Multiple GP Visits
Patients requiring multiple visits before evaluation
85%
Ten or More Visits
Patients visiting GP 10+ times before diagnosis
One contributing factor is the overlap between dysmenorrhea and endometriosis symptoms. Since not all patients with typical symptoms have the disease, other evaluation and treatment approaches are often tried first.
Physical Examination Findings
Examination Approach
Comprehensive evaluation includes abdominal, bimanual, and digital rectal examination (for patients with bowel symptoms). Physical findings vary depending on lesion location and size.
Suggestive Findings
  • Focal vaginal tenderness
  • Posterior fornix nodules
  • Adnexal masses
  • Cervical or uterine immobility
  • Lateral cervical placement
While physical examination findings are helpful, the examination can be normal even in the presence of disease. Lack of findings does not exclude endometriosis.
Laboratory Testing
No Pathognomonic Tests
There are no laboratory findings specific to endometriosis. Several biomarkers have been studied but none are clinically useful for diagnosis.
CA-125 Limitations
While CA-125 can be elevated (>35 units/mL) in endometriosis, it's not routinely ordered as many other diseases also elevate this marker, notably ovarian carcinoma.
Other Biomarkers
Interleukin-6 (IL-6) and various urinary, serum, and endometrial biomarkers have been studied but lack clinical utility for diagnosis.
Imaging: The First-Line Approach
Transvaginal Ultrasound
Pelvic ultrasound, typically transvaginal, is recommended as part of initial diagnostic evaluation. While imaging doesn't replace histologic diagnosis, typical findings make endometriosis highly likely.
Imaging helps identify other potential causes of symptoms and guides surgical planning. However, no imaging modality surpasses laparoscopic evaluation, and negative studies cannot exclude endometriosis, particularly superficial peritoneal disease.
Imaging Modalities Compared
Transvaginal Ultrasound
Initial imaging study due to availability, low cost, and ability to identify endometriosis and other pathology. Sensitivity and specificity similar to MRI for rectovaginal endometriosis, though operator-dependent.
Magnetic Resonance Imaging
Beneficial for unclear ultrasound findings or suspected bowel, bladder, or ureteral disease. MRI during menses is more sensitive for detecting diaphragmatic implants.
Key Imaging Findings
Ovarian Cysts
Endometriomas appear as characteristic cysts on ultrasound and MRI
Rectovaginal Nodules
Deep infiltrating lesions visible on transvaginal sonography
Bladder Lesions
Detrusor nodules identified on imaging studies
Abdominal Wall
Hypoechoic, vascular masses with irregular margins
Diagnostic Approaches: Making the Choice
The surgical diagnosis of endometriosis has traditionally been the gold standard. However, presumptive clinical diagnosis based on symptoms, physical examination, and imaging has gained favor, especially for starting low-risk interventions.
Presumptive Diagnosis
Favored for individuals without endometriomas, with mild-to-moderate symptoms, who desire trial of low-risk medications (NSAIDs, acetaminophen, hormonal contraception) and prefer to avoid surgery.
Surgical Diagnosis
Favored for individuals with severe symptoms, inadequate response to low-risk therapies, and those who value definitive confirmation. Advantage: treatment can occur simultaneously.
Presumptive Clinical Diagnosis
01
Ultrasound Evaluation
Assess for endometriosis findings and exclude other causes
02
Visual Inspection
Examine posterior vaginal fornix with biopsy if lesions present
03
Cystoscopy
Include biopsy of visible detrusor lesions if present
04
Physical Examination
Evaluate for evidence of rectovaginal endometriosis

Important: Treatment response cannot definitively confirm or exclude diagnosis. Presumptive diagnosis requires clinicians with significant expertise in examination, sonography, and cystoscopy.
Surgical Diagnosis: The Gold Standard
When Surgery Is Indicated
Surgery, usually performed laparoscopically, allows both definitive diagnosis and treatment. Typical indications include evaluation of severe pain limiting function, persistent pain unresponsive to medical therapy, and treatment of anatomic abnormalities.
Endometriosis is definitively diagnosed by histologic evaluation of lesions biopsied during surgery. While visual confirmation alone is considered diagnostic by some, accuracy is impacted by disease stage, location, and surgeon expertise.
Visual Appearance of Lesions
The gross appearance and size of endometriosis implants vary considerably at surgery. During laparoscopy, peritoneal endometriosis appears in multiple forms:
Flame-like Patches
Raised, reddish lesions with characteristic appearance
Whitish Opacifications
Pale, cloudy areas on peritoneal surfaces
Yellow-Brown Discolorations
Classic "powder burn" appearance
Translucent Blebs
Clear, fluid-filled lesions
Reddish-Blue Islands
Irregularly-shaped vascular lesions
Surgical Staging Systems
Surgical staging is performed at diagnostic laparoscopy, typically following the revised American Society for Reproductive Medicine (ASRM) scoring system. While multiple classification systems exist, the Endometriosis Fertility Index (EFI) has the strongest correlation with patient outcomes.
1
Stage I: Minimal
Isolated implants, no significant adhesions
2
Stage II: Mild
Superficial implants <5cm, scattered, no significant adhesions
3
Stage III: Moderate
Multiple superficial and deep implants, peritubal/periovarian adhesions
4
Stage IV: Severe
Multiple implants, large endometriomas, filmy and dense adhesions
Medical Treatment: First-Line Approach
NSAIDs and Hormonal Contraceptives
First-line treatment combines NSAIDs with continuously dosed hormonal contraceptives. These therapies are low-risk, have few side effects, and relieve symptoms for many patients.
Selection between estrogen-progestin or progestin-only therapy is based on patient preferences around hormone content, administration route, dosing frequency, contraceptive efficacy, and adverse effects. Individuals who cannot use NSAIDs may use acetaminophen instead.
NSAID Options
Ibuprofen
400mg orally every 4-6 hours, maximum 2400mg per 24 hours
Acetaminophen
650mg orally every 4-6 hours, maximum 3000mg per 24 hours (for those unable to use NSAIDs)

Note for Fertility: Individuals desiring pregnancy can use NSAIDs, but selective COX-2 inhibitors (celecoxib, rofecoxib, valdecoxib) should be avoided as they may prevent or delay ovulation.
Combined Estrogen-Progestin Contraceptives
Why First-Line?
Combined oral contraceptives (COCs), transdermal patches, and vaginal rings are often first-line treatment due to general availability and lower cost compared with long-acting methods.
Extended- or continuous-dosing regimens are preferred to reduce or avoid withdrawal bleeding. Supporting data shows these methods effectively reduce endometriosis-related pain.
Mechanism of Action
Suppress ovarian function, reducing endometriosis disease activity and pain. Progestin-induced decidualization leads to subsequent atrophy of endometrial tissue.
May also slow disease progression, though evidence is conflicting.
Progestin-Only Treatment Options
Oral Progestins
Norethindrone, drospirenone, or norethindrone acetate 5mg daily. Dienogest 2mg daily (available outside US).
DMPA Injections
150mg intramuscularly or 104mg subcutaneously every three months. Provides highly effective contraception.
Etonogestrel Implant
Long-acting subdermal implant providing continuous hormone delivery and contraception.
LNG IUDs
Levonorgestrel intrauterine devices provide local hormone delivery and highly effective contraception.
Assessing Treatment Response
Patients are typically reassessed three to four months after initiating NSAID/hormonal treatment. Next steps depend on treatment response:
Patients with adequate symptom improvement continue this approach until pregnancy is desired or menopause is reached. Those with persistent severe symptoms are offered next-line therapies, typically after surgical diagnosis if not yet performed.
Second-Line Treatment: GnRH Antagonists
Oral Dosing with Reduced Side Effects
GnRH antagonists include elagolix (Orilissa) and relugolix combination therapy (Myfembree). These medications offer advantages over agonists: oral dosing, less impact on bone mineral density, and for relugolix, integrated add-back therapy.
Patients treated for up to 2 years had mean bone mineral density loss of <1%, with most loss occurring by 36 weeks then remaining stable. These advantages make antagonists more commonly used than agonists for persistent symptoms.
GnRH Antagonist Efficacy
75%
Elagolix Low-Dose
Dysmenorrhea responders at 6 months
85%
Relugolix Combination
Dysmenorrhea responders at 6 months
76%
Nonmenstrual Pain
Relugolix responders at 6 months
Patients reported clinically meaningful and sustained improvements in both dysmenorrhea and nonmenstrual pelvic pain. At 2 years, 91% of patients were opioid-free and 75% were analgesic-free.
GnRH Agonists: Alternative Option
Available Agents
  • Nafarelin (intranasal)
  • Leuprolide (injection)
  • Goserelin (implant)
  • Buserelin (where available)
Treatment Approach
GnRH agonist and add-back therapy should be started simultaneously to limit bone loss, reduce vasomotor symptoms, and improve compliance without reducing efficacy.
Common regimens include leuprolide acetate 3.75mg IM monthly or 11.25mg IM every three months, and intranasal nafarelin 200mcg twice daily.
Refractory Symptoms: Additional Options
1
Danazol
Effective but limited by androgenic side effects including acne, weight gain, hirsutism, and voice deepening. Typically 400-800mg daily for six months.
2
Aromatase Inhibitors
Reserved for severe, refractory pain. Anastrozole 1mg or letrozole 2.5mg daily, combined with GnRH analog, norethindrone acetate, or oral contraceptive. Off-label use requires counseling.
3
Neuropathic Pain Treatment
Offered to patients with persistent pain despite above treatments. Addresses central sensitization component.
Complementary Therapies
Pelvic Floor Physical Therapy
Common treatment for chronic pelvic pain that appears to reduce pain in adolescent and adult patients with endometriosis. Addresses pelvic muscle spasm.
Acupuncture
Limited evidence available. One trial showed auricular acupuncture more effective than Chinese herbal medicine for treating dysmenorrhea.
Cognitive Therapy
In-person, virtual, and internet-based cognitive therapies improve patients' ability to manage pain symptoms. Low-risk adjuvant treatment option.
Surgical Management: General Principles
A Lifelong Management Approach
Endometriosis should be viewed as a chronic disease requiring lifelong management with the goal of maximizing medical treatment and avoiding repeated surgical procedures.
Treatment decisions are individualized considering clinical presentation, symptom severity, disease extent and location, reproductive desires, patient age, medication side effects, surgical complication rates, and cost.
When to Consider Surgery
Persistent Pain
Pain that continues despite adequate medical therapy trials
Contraindications or Refusal
Medical therapy contraindicated or patient preference against medications
Tissue Diagnosis Needed
Requirement for histologic confirmation of endometriosis
Malignancy Exclusion
Adnexal mass requiring evaluation to exclude cancer
Obstruction
Bowel or urinary tract obstruction requiring intervention
Conservative vs. Definitive Surgery
Conservative Surgery
Excision or ablation of endometriotic lesions preserving the uterus and as much ovarian tissue as possible. First-line option for most women as it preserves fertility and hormone production.
Advantages: Less invasive, preserves reproductive function, documented short-term efficacy
Disadvantages: Higher recurrence rates, may require repeat procedures
Definitive Surgery
Hysterectomy with or without bilateral salpingo-oophorectomy. Reserved for women who have completed childbearing and failed other treatments.
Advantages: Lower long-term reoperation rates, more definitive treatment
Disadvantages: Loss of fertility, surgical risks, potential premature menopause
Recurrence Rates After Surgery
The rate of recurrent symptoms varies significantly by surgical approach and time elapsed from index surgery:
58%
Conservative Surgery
Reoperation rate at 7 years with ovarian conservation
19%
Hysterectomy
Reoperation rate at 7 years with ovarian conservation
8%
Hysterectomy + BSO
Reoperation rate at 7 years with bilateral oophorectomy
Cumulative recurrence rates after conservative surgery: 0.9% at 1 year, 13.5% at 3 years, and 40.3% at 5 years from index surgery.
Role of Bilateral Oophorectomy
Balancing Benefits and Risks
Women who benefit from oophorectomy include those with extensive adnexal disease and those for whom reoperation risks outweigh premature menopause risks. However, there's no established age-based cut-off.
Oophorectomy creates a postmenopausal state, theoretically reducing estrogen-dependent endometriosis pain. However, early menopause (age 44 or younger) increases risks of overall mortality, cardiovascular disease, neurologic disease, osteoporosis, and psychiatric illness.
Laparoscopy: The Preferred Approach
Improved Visualization
Lens magnification provides superior surgical visualization
Less Pain
Minimally invasive approach reduces postoperative discomfort
Shorter Hospital Stay
Most patients discharged same day or next day
Quicker Recovery
Faster return to normal activities and work
Better Cosmetic Outcome
Small incisions result in minimal scarring
Laparoscopy is performed for the majority of endometriosis procedures, regardless of disease severity. Laparotomy may be necessary for extensive adhesions or invasive disease near critical structures.
Preoperative Evaluation
Preoperative evaluation includes studies pertinent to symptoms plus routine preoperative assessment. Findings suggestive of deep infiltrating endometriosis (DIE) or extrapelvic disease aid surgical planning.
01
Symptom-Specific Testing
Cystoscopy for urinary symptoms, colonoscopy for hematochezia
02
Imaging Assessment
Ultrasound "sliding sign" for adhesions, MRI for deep disease
03
Multidisciplinary Planning
Coordinate with general surgery, urology as needed
Preoperative Preparation
What to Do
  • Comprehensive informed consent discussion
  • Thromboprophylaxis based on risk factors
  • Antibiotic prophylaxis if bowel/vaginal surgery likely
  • Document surgical plan and alternatives
What to Avoid
  • Preoperative medical suppression (no proven benefit)
  • Routine mechanical bowel preparation
  • Oral antibiotics beyond parenteral prophylaxis
  • Delaying surgery for hormonal treatment
Surgical Exploration and Diagnosis
Systematic Approach
Initial exploration involves thorough inspection of the pelvis for endometriotic lesions, determining lesion locations and characteristics. Key steps include:
  • Inspect reproductive organs, ligaments, peritoneal surfaces, and sigmoid colon
  • Perform bimanual examination while observing posterior cul-de-sac
  • Evaluate appendix (2-4% have appendiceal endometriosis)
  • Explore extrapelvic sites based on patient history
  • Use dye to stain peritoneum and identify subtle lesions
  • Assess for deep infiltrating endometriosis
Ablation vs. Excision
Ablation
Eradication of lesions by laser vaporization, electrosurgical fulguration, or ultrasonic cutting and coagulation. Effective for superficial lesions.
Excision
Removal of lesions, typically with laparoscopic scissors. Recommended for deep lesions as ablative techniques may not penetrate sufficiently or may injure underlying structures.
A 2021 systematic review found no significant difference in pain outcomes at one year between excision and ablation of superficial lesions. However, excision is preferred for deep endometriosis and for obtaining tissue for histologic confirmation.
Adhesiolysis: Selective Approach
Women with endometriosis often develop intraperitoneal adhesive disease, reported in up to 70% of patients. However, adhesions often reform postoperatively, potentially exacerbating pain or infertility.
When to Perform
Resect adhesions that may compromise fertility or correspond to location of patient's pain
When to Avoid
Comprehensive adhesiolysis may be unwarranted due to injury risk to critical structures combined with lack of consistent benefit
Surgical Outcomes: Pain Reduction
Most patients achieve initial pain relief after surgery. In a systematic review, patients who underwent operative laparoscopy were three times more likely to report improvement in pain at 12 months compared with diagnostic laparoscopy alone.
73%
Operative Laparoscopy
Patients reporting pain improvement at 12 months
21%
Diagnostic Only
Control group with pain improvement
However, risks of recurrent pain and repeat surgery vary by surgical type and time elapsed. Repeat surgery rates are lowest for hysterectomy with bilateral oophorectomy.
Risk Factors for Recurrence
Surgical Factors
Incomplete excision, ovarian cyst drainage vs. excision, ovarian conservation
Associated Factors
Abdominal wall pain, pelvic floor myalgia, depression scores
Advanced Disease
Stage III-IV disease has higher recurrence than stage I-II (14% vs 6% at 2 years)
Age Factor
Younger age at surgery associated with higher recurrence risk over time
Postoperative Medical Therapy
Secondary Prevention
Long-term medical suppressive therapy (6-24 months) is recommended for most women treated surgically for endometriosis. This approach reduces dysmenorrhea recurrence and avoids need for multiple surgeries.
Best evidence supports levonorgestrel-releasing intrauterine device (LNG IUD) and oral contraceptive pills for prevention of anatomical relapse or symptom recurrence. GnRH analogs also delay symptom return but have more adverse effects.
Postoperative Treatment Options
Estrogen-Progestin Contraceptives
First-line, well-tolerated, low-risk, cost-effective
Oral Progestins
Alternative first-line option, various formulations available
LNG IUD
Long-acting option with local hormone delivery
GnRH Analogs
For inadequate response to first-line options
Hormone Therapy After Oophorectomy
Menopausal Symptoms
Following bilateral oophorectomy, hormonal treatment may be necessary for hot flushes, night sweats, and sleep disturbance. No strong evidence suggests hormone therapy should be avoided.
Therapy can be initiated immediately after surgery without waiting period.
Treatment Approach
After hysterectomy: Estrogen-only therapy (no advantage to adding progesterone)
Uterus retained: Combined therapy with low-dose estrogen; consider micronized progesterone for lower breast cancer risk
Repeat Surgery Considerations
Pelvic pain symptoms often recur after conservative surgical treatment. When patients present with recurrent pain, evaluation ensures endometriosis is the most likely cause.
There are limited data on repeat conservative surgery efficacy. Decisions are individualized based on response to previous surgery, ability to tolerate medical therapy, and patient age. No established maximum number of procedures exists.
Extrapelvic Endometriosis Sites
Diaphragm
Multiple superficial lesions, some penetrating deeper. Catamenial right shoulder pain, worsening when recumbent. Deep lesions require full-thickness resection.
Umbilicus
0.5-1% of extrapelvic disease. Cyclic pain and bleeding in inferior umbilicus. Usually secondary to laparoscopic surgery. Wide-local excision is treatment of choice.
Abdominal Wall
Often in cesarean section scars. Presents as mass with menstrual pain. Wide-local excision with frozen section confirms clear margins. Cures pain in >95%.
Inguinal Canal
Groin lump with menstrual pain, size fluctuation. Right side affected 90% of time. Wide-local excision with laparoscopy; 91% have intraabdominal disease.
Special Populations: Infertility
Different Treatment Approach
Women with infertility and endometriosis-related pain are not candidates for hormone suppression therapies because hormonal suppression prevents pregnancy and does not improve fertility.
Treatment involves a combination of surgery and assisted reproduction technology. NSAIDs are offered for pain management. A stepwise approach to infertility treatment is essential for these patients.
Deep Infiltrating Endometriosis
Deep infiltrating endometriosis involves the uterosacral ligaments, rectovaginal septum, bowel, ureters, or bladder. Management is impacted by presenting symptoms, lesion location, and patient preference.
1
Asymptomatic
Expectant management supported by studies
2
Bothersome Symptoms
Medical therapy with hormonal suppression appropriate
3
Obstruction
Surgery indicated for ureteral or bowel obstruction
4
Failed Medical Management
Surgery for persistent symptoms despite treatment
Quality of Life Impact
Endometriosis significantly affects multiple aspects of life beyond physical symptoms:
Physical Pain
Chronic pain affecting daily activities and function
Sexual Health
Dyspareunia impacting intimate relationships
Work Productivity
Missed work days and reduced performance
Mental Health
Depression, anxiety, and emotional distress
Fertility Concerns
Impact on reproductive goals and family planning
Social Life
Limitations on activities and social engagement
Patient Resources and Support
Endometriosis.org
Nonprofit website dedicated to information about endometriosis and treatment options
ESHRE Guidelines
European Society guidelines with patient information in multiple languages and management guidelines for clinicians
ACOG Resources
American College of Obstetricians and Gynecologists frequently asked questions about endometriosis
Young Women's Health
Informational site sponsored by Boston Children's Hospital for adolescents and young adults
Endometriosis Association
Independent nonprofit self-help organization for women with endometriosis, clinicians, and interested parties
Key Takeaways: Diagnosis
Clinical Presentation
Peak prevalence 25-35 years. Common symptoms: pelvic pain, dysmenorrhea, dyspareunia, infertility. Diagnostic delay averages 7-8 years.
Physical Examination
Variable findings depending on lesion location and size. Suggestive findings include posterior fornix tenderness, nodules, adnexal masses, cervical/uterine immobility. Normal exam doesn't exclude disease.
Imaging
Transvaginal ultrasound recommended as initial evaluation. MRI for unclear findings or suspected deep disease. Findings include endometriomas, rectovaginal nodules, bladder lesions.
Diagnostic Approaches
Presumptive diagnosis based on symptoms, exam, imaging for low-risk treatment initiation. Surgical diagnosis with histology for definitive confirmation, severe symptoms, or inadequate response to treatment.
Key Takeaways: Treatment and Management
Medical Treatment
First-line: NSAIDs plus hormonal contraceptives (estrogen-progestin or progestin-only). Second-line: GnRH antagonists or agonists. Refractory: danazol or aromatase inhibitors. Postoperative suppression recommended for 6-24 months.
Surgical Management
Conservative surgery (excision/ablation) first-line for most patients, preserving fertility. Definitive surgery (hysterectomy ± oophorectomy) for completed childbearing and failed other treatments. Laparoscopy preferred approach.
Outcomes
Initial pain relief in ~75% after surgery. Recurrence rates vary: 58% at 7 years after conservative surgery, 19% after hysterectomy with ovarian conservation, 8% after hysterectomy with bilateral oophorectomy.
Comprehensive Care
Lifelong management approach maximizing medical therapy, minimizing repeat surgeries. Complementary therapies: pelvic floor PT, cognitive therapy. Patient education and support resources essential.